Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07503002 · ClinicalTrials.gov registry record · Phase 1
Shortened LSD Intervention for Major Depressive Disorder
A Phase 1 study, sponsored by Johns Hopkins University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT07503002: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT07503002 is a Phase 1 study that has not yet begun recruiting, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07503002, a Phase 1 study, has not yet begun recruiting, sponsored by Johns Hopkins University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.
Interventions
- DRUG LSD
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07503002
The ClinicalTrials.gov registry entry for NCT07503002 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LSD is the first listed.
NCT07503002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07503002 about?
NCT07503002 is a clinical study titled "Shortened LSD Intervention for Major Depressive Disorder". The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.
What is the current status of trial NCT07503002?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2026-07-01. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07503002?
The interventions under investigation include: LSD (DRUG), Risperidone (DRUG).
Who is sponsoring clinical trial NCT07503002?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.